The letters from Republicans on the House Oversight Committee, first reported by BuzzFeed News, warn pharmaceutical CEOs that information provided to the committee could be leaked to the public. Specifically, the letters imply that committee chair Sen. Elijah Cummings, D-Md., may share details to negatively affect their stock prices.
The letters from Republican representatives come after Mr. Cummings requested information from 12 drug companies as part of a broad investigation into industry pricing practices.
Mr. Cummings is seeking sensitive information “that would likely harm the competitiveness of your company if disclosed publicly,” the letters read.
The letters were sent to AbbVie; Amgen; AstraZeneca; Celgene; Eli Lilly; Johnson & Johnson; Mallinckrodt; Novartis; Novo Nordisk; Pfizer; Sanofi; and Teva Pharmaceuticals.
Read more here.
More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.